New or worsening hematologic laboratory abnormalities occurring in at least 30% of patients receiving parsaclisib monotherapy (safety population)
| Total (N = 72) . | Any grade, n (%) . | Grade 3, n (%) . | Grade 4, n (%) . |
|---|---|---|---|
| Leukopenia | 36 (50) | 6 (8) | 0 |
| Neutropenia | 32 (44) | 10 (14) | 4 (6) |
| Lymphopenia | 25 (35) | 13 (18) | 2 (3) |
| Thrombocytopenia | 25 (35) | 2 (3) | 5 (7) |
| Anemia | 22 (31) | 6 (8) | NA |
| Total (N = 72) . | Any grade, n (%) . | Grade 3, n (%) . | Grade 4, n (%) . |
|---|---|---|---|
| Leukopenia | 36 (50) | 6 (8) | 0 |
| Neutropenia | 32 (44) | 10 (14) | 4 (6) |
| Lymphopenia | 25 (35) | 13 (18) | 2 (3) |
| Thrombocytopenia | 25 (35) | 2 (3) | 5 (7) |
| Anemia | 22 (31) | 6 (8) | NA |
Based on reported laboratory values.
NA, not applicable.